Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parkinson's Disease and Patients With Multiple System Atrophy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The primary objective of this study is to assess the safety and tolerability of exidavnemab after multiple dosing versus placebo.
Epistemonikos ID: 3b70c20b909e3aed0fda988463146bcda04e116a
First added on: Apr 17, 2026